Resource impact summary report
Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Population and treatments' and 'Unit costs' worksheets in the template to reflect local data and assumptions.
Guidance recommendations
Financial and capacity resource impact
The key drivers of resource impact are:
-
the average treatment duration of epcoritamab and comparators
-
that epcoritamab is administered subcutaneously but most comparators are administered intravenously.
The company has a commercial arrangement. This makes epcoritamab available to the NHS at a discount.
The payment mechanism for epcoritamab is determined by the responsible commissioner and depends on whether it is classified as high cost.
Eligible population for epcoritamab
Table 1 shows the population eligible for epcoritamab and the number of people who are expected to have epcoritamab in each of the next 3 years, excluding forecast population growth.
| Eligible population and uptake | Number of people eligible for epcoritamab | Uptake for epcoritamab | Number of people starting epcoritamab each year |
|---|---|---|---|
|
Current practice without epcoritamab |
307 |
0% |
0 |
|
Year 1 |
307 |
70% |
215 |
|
Year 2 |
307 |
70% |
215 |
|
Year 3 |
307 |
70% |
215 |
Treatment options for the eligible population
Comparator treatments for the eligible population include various combinations of chemotherapy and rituximab-based treatment. The resource impact template includes rituximab with bendamustine, lenalidomide with rituximab, and obinutuzumab with bendamustine, all of which are administered intravenously. It also includes chlorambucil chemotherapy, which is administered orally. Epcoritamab is administered subcutaneously.
Key information
| Time from publication to routine commissioning funding |
90 days |
|---|---|
| Programme budgeting category |
PBC 02L |
| Commissioner |
NHS England |
| Providers |
NHS hospital trusts |
| Pathway position |
3rd line and later |
About this resource impact summary report
This resource impact summary report accompanies the NICE technology appraisal guidance on epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment and should be read with it.
ISBN: 978-1-4731-9399-4
This page was last updated: